Dr. Subhash Chauhan, professor of Pharmaceutical Sciences, was awarded a $600K three year grant from the Department of Defense (DOD) to investigate the role of ormeloxifene for prostate cancer prevention and treatment. Dr. Chauhan is a professor of Pharmaceutical Sciences. The current role of ormeloxifene, a selective estrogen receptor modulator, is as a once weekly contraceptive. It is available in India and 28 other countries; however, it is not available in the United States as a contraceptive. This research has the potential to produce a novel therapeutic modality for advanced-stage prostate cancer treatment. Dr. Chauhan will be the primary investigator for the study and Dr. Meena Jaggi, associate professor of Pharmaceutical Sciences, will be his co-primary investigator. Other co-investigators for the project include Dr. Murali Mohan Yallapu, assistant professor of Pharmaceutical Sciences , Nadeem Zafar, and Jim Wan.